St. Louis Trust Co Buys New Position in Axon Enterprise, Inc $AXON

Posted by Geri Gentry on May 24th, 2026

St. Louis Trust Co bought a new stake in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 1,524 shares of the biotechnology company’s stock, valued at approximately $866,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. raised its position in Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock valued at $5,319,928,000 after buying an additional 53,060 shares during the last quarter. Baillie Gifford & Co. raised its position in Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock valued at $932,869,000 after buying an additional 1,516,099 shares during the last quarter. Jennison Associates LLC raised its position in Axon Enterprise by 53.8% in the 3rd quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after buying an additional 330,213 shares during the last quarter. Massachusetts Financial Services Co. MA raised its position in Axon Enterprise by 23.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 838,289 shares of the biotechnology company’s stock valued at $476,089,000 after buying an additional 156,647 shares during the last quarter. Finally, Northern Trust Corp raised its position in Axon Enterprise by 1.6% in the 3rd quarter. Northern Trust Corp now owns 743,926 shares of the biotechnology company’s stock valued at $533,871,000 after buying an additional 11,726 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Down 1.0%

AXON stock opened at $386.00 on Friday. The company has a quick ratio of 1.93, a current ratio of 2.27 and a debt-to-equity ratio of 0.49. The business has a 50 day moving average price of $416.52 and a two-hundred day moving average price of $503.10. The company has a market cap of $31.11 billion, a price-to-earnings ratio of 155.02, a P/E/G ratio of 7.02 and a beta of 1.44. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $885.91.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. The firm had revenue of $807.35 million during the quarter, compared to the consensus estimate of $778.91 million. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The business’s revenue was up 33.7% compared to the same quarter last year. During the same period last year, the company earned $1.47 earnings per share. Analysts anticipate that Axon Enterprise, Inc will post 1.82 EPS for the current fiscal year.

Insider Transactions at Axon Enterprise

In other news, CAO Jennifer H. Mak sold 1,500 shares of Axon Enterprise stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total transaction of $860,175.00. Following the completion of the transaction, the chief accounting officer directly owned 12,240 shares in the company, valued at approximately $7,019,028. The trade was a 10.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Isaiah Fields sold 2,000 shares of Axon Enterprise stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $535.01, for a total value of $1,070,020.00. Following the transaction, the insider owned 55,588 shares of the company’s stock, valued at $29,740,135.88. This represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 13,855 shares of company stock valued at $7,109,828. 4.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

AXON has been the topic of a number of recent research reports. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, February 25th. Weiss Ratings raised Axon Enterprise from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Friday, May 8th. Wall Street Zen upgraded Axon Enterprise from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Barclays decreased their price target on Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Craig Hallum restated a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $712.75.

Get Our Latest Stock Analysis on Axon Enterprise

About Axon Enterprise

(Free Report)

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.